English | 简体中文 | 繁體中文 | 한국어 | 日本語
Tuesday, 26 July 2022, 10:27 JST
Share:
    

Source: Eisai
Eisai Listed for 21st Consecutive Year in FTSE4Good Index Series

TOKYO, July 26, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 21st consecutive year since its initial inclusion in 2002. The FTSE4Good Index Series is a global index series for socially responsible investment.

The FTSE4Good Index Series was developed by FTSE Russell to promote investment in companies that meet global environmental, social and governance (ESG) standards. Eisai received particularly high scores in "Corporate Governance", "Customer Responsibility", "Labor Standards" and "Tax Transparency", among others. As of the end of June 2022, 1,092 companies worldwide and 224 Japanese companies were included in the FTSE4Good Developed Index Series.

Currently, in addition to the MSCI ESG Leaders Indexes, another global ESG investment index, Eisai is also listed in the FTSE Blossom Japan Index, the FTSE Blossom Japan Sector Relative Index, the MSCI Japan ESG Select Leaders Index, the MSCI (WIN) and the S&P/JPX Carbon Efficient Index, which are ESG investment indices for Japanese stocks Japan Empowering Women Index adopted by the Government Pension Investment Fund (GPIF).

Eisai's corporate concept is to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides to them, as well as address diverse healthcare needs worldwide. By strengthening its ESG initiatives and increasing non-financial value, Eisai is striving to sustainably enhance corporate value based on this concept.

For more information on our ESG initiatives, please visit www.eisai.com/sustainability/index.html.

Media Inquiries:
Public Relations Department
Eisai Co., Ltd.
+81-(0)3-3817-5120

Topic: Press release summary
Source: Eisai

Sectors: BioTech
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Eisai Related News
Wednesday, 30 April 2025, 14:17 JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
Friday, 18 April 2025, 16:52 JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
2025年4月16日 11時30分 JST
エーザイとバイオジェン、「レケンビ」(レカネマブ)が欧州連合(EU)において早期アルツハイマー病の進行を抑制する初めての治療剤として承認を取得
Tuesday, 1 April 2025, 13:15 JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
2025年3月27日 8時40分 JST
エーザイ、アルツハイマー・パーキンソン病学会において、レカネマブの長期実臨床データやバイオマーカーをはじめとするアルツハイマー病の最新成果を発表
More news >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575